Lifesci Capital Issues Positive Estimate for CNTX Earnings

Key Points

• Lifesci Capital raised its Q2 2026 EPS estimate for Context Therapeutics to -$0.09 from -$0.13 and kept a Strong-Buy rating on the stock.
• The firm also lifted its longer-term outlook, forecasting smaller losses for Q3 2026, Q4 2026, and full-year 2026, though Context Therapeutics is still expected to remain unprofitable.
• Other analysts are generally constructive on CNTX, with a Moderate Buy consensus and an average price target of $6.60, while the stock recently traded around $2.38.

Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Lifesci Capital upped their Q2 2026 earnings per share (EPS) estimates for shares of Context Therapeutics in a research note issued to investors on Wednesday, May 6th. Lifesci Capital analyst C. Zhu now forecasts that the company will earn ($0.09) per share for the quarter, up from their prior forecast of ($0.13). Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.35) per share. Lifesci Capital also issued estimates for Context Therapeutics' Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.41) EPS.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen upgraded Context Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Guggenheim restated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a report on Tuesday, March 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Context Therapeutics in a report on Monday, April 20th. Piper Sandler upped their price target on Context Therapeutics from $4.00 to $7.00 and gave the stock an "overweight" rating in a report on Tuesday, March 24th. Finally, D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Context Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $6.60.

Context Therapeutics Stock Performance

Shares of CNTX stock opened at $2.38 on Monday. The company has a market cap of $218.67 million, a price-to-earnings ratio of -5.67 and a beta of 1.57. The stock has a 50 day simple moving average of $2.62 and a 200-day simple moving average of $1.90. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $3.62.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in Context Therapeutics in the fourth quarter valued at about $43,000. State Street Corp raised its position in Context Therapeutics by 8.5% in the fourth quarter. State Street Corp now owns 165,607 shares of the company's stock valued at $243,000 after purchasing an additional 13,000 shares during the period. Clear Harbor Asset Management LLC raised its position in Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company's stock valued at $90,000 after purchasing an additional 35,000 shares during the period. Sanctuary Advisors LLC purchased a new position in Context Therapeutics in the first quarter valued at about $51,000. Finally, Citadel Advisors LLC purchased a new position in Context Therapeutics in the third quarter valued at about $100,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Context Therapeutics

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised its 2026 EPS estimates and maintained a Strong-Buy rating, suggesting improved expectations for Context Therapeutics’ near-term financial performance.
• Positive Sentiment: HC Wainwright also increased EPS forecasts for 2026 through 2029, indicating analysts see a better long-term earnings path for Context Therapeutics.
• Neutral Sentiment: Despite the upgrades, the company is still expected to report losses in each forecast period, so the revisions reflect reduced losses rather than a move to profitability.

About Context Therapeutics

Context Therapeutics NASDAQ: CNTX is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company's research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.